Continuous glucose monitor for Diabetes, Gestational

Diabetes affected 8.3% of US women in 2006 and 5% in 2008/2009. Of women presenting for care, diabetes prevalence varied substantially by region, ethnicity, age and obesity. Diabetes prevalence in US births was 7.7% in 2006/2007. In the absence of a national diabetes surveillance program and reporting requirements, current estimates of diabetes prevalence in US women of childbearing age and US pregnant women are not reliable to understand the prevalence of diabetes and its complications in the US population.

Diabetes during pregnancy increases the risk of most of the serious adverse outcomes of pregnancy. Gestational diabetes is characterized by insulin imbalance, gestational hypertension, and fetal macrosomia/microsomia (fetal growth patterns).\n

With proper management, gestational diabetes can be cured. However, it should be recognized that pregnancy can be a stressful experience for both women and their unborn babies. With appropriate advice and supportive care, gestational diabetes and pregnancy can lead to successful pregnancies with healthy babies.

The pathogenesis of diabetes, gestational is multifactorial, and the major pathophysiological mechanisms are insulin resistance and impaired insulin secretion. The key to the genesis of gestational diabetes is an increased secretion of proinflammatory cytokines, and a decreased insulin secretion.

Diabetes is often treated with oral antidiabetic agents and insulin. Gestational diabetes is treated with dietary measures and medication to stop its symptoms. Both are common conditions that require close management.

Diabetes in pregnancy is characterized by nausea and vomiting, thirst and frequent urination. Other signs of diabetes include an elevated blood glucose level and gestational diabetes. Pregnancy can occur in women with diabetes and without a history of the illness.

There is increased knowledge, and a tendency to focus on prevention and treatments of diabetes. As knowledge and understanding of diabetes evolves, there is a need to provide information and support for people with diabetes and their families. It is important that healthcare providers have information and support for people with diabetes and their families.

We suggest the use of CGM in patients not only using multiple treatments but also in those with a long duration of diabetes (e.g. more than 5 years). In the patients who have been treated with insulin for more than 5 years, the effects of long-term use of insulin on blood glucose and insulin sensitivity may be a contraindication for CGM use. However, the potential benefits of CGM should be weighed against the risks of using it.

On the basis of the present data, it would appear that CGMS has proven to minimize glucose variability, with less hypoglycemic events in comparison to control group. Therefore, this promising device seems to be potentially useful in type 2 diabetes management, especially with regard to the patients not achieving glycemic control through conventional pharmacological therapies.

Diabetes, gestational diabetes, and gestational hypertension have low absolute and relative contribution to clinical trials but should all be screened. The majority of women consider clinical trials for gestational diabetes.

CGMs resulted in meaningful reductions in glycemia in all respondents, despite a few shortcomings. There was minimal impact on the overall QOL or bother, except for those who reported a sense of well-being.